Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer

Author(s)

Ferreira, Janaina Mendes ^[1] ; Delle, Humberto ^[1] ; Camacho, Cleber Pinto ^[1] ; Almeida, Robson Jose ^[1] ; Reis, Sabrina Thalita ^[2] ; Matos, Yves Silva Teles ^[1] ; Lima, Amanda M. Ramos ^[1] ; Leite, Katia Ramos Moreira ^[2] ; Pontes-Junior, Jose ^{[1, 2]} ; Srougi, Miguel ^[2]

Affiliation

^[1] Univ Nove Julho UNINOVE, Postgrad Program Med, Rua Vergueiro 235, 2 Subsolo, Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Urol Dept, Lab Med Invest LIM55, Sch Med, Sao Paulo - Brazil

• Document type: Journal article
• Source: INTERNATIONAL UROLOGY AND NEPHROLOGY; v. 52, n. 8, p. 1477-1482, AUG 2020.
• Web of Science Citations: 0

Abstract

Background Indoleamine 2,3-dioxygenase (IDO1) is an enzyme that acts as an immunomodulatory molecule. It is found in several types of cancer where it seems to be associated with tumor escape due to its immunosuppressive mechanisms. However, the role of IDO1 expression in prostate cancer (PC) is unclear. The aim of our study was to evaluate the expression of IDO1 in localized PC and to correlate with the classic prognostic factor and recurrence after surgical treatment. Methods We retrospectively evaluated surgical specimens from 111 patients with localized PC, who underwent radical prostatectomy. Recurrence was defined as a prostate specific antigen (PSA) level exceeding 0.2 ng/mL postoperatively, and the follow-up was 123 months. IDO1 expression was evaluated by immunohistochemistry in 72 cases of which 42 (58%) had biochemical recurrence. Results Lower IDO1 expression was associated with higher Gleason score (p = 0.022) and PSA levels (p = 0.042). The multivariate analyses revealed that the loss of IDO1 and higher PSA were independently associated with biochemical recurrence. The chance of recurrence was increased by 85% in patients with lower IDO1 {[}OR = 0.15;p = 0.009 CI 95% (0.038-0.633)] and increased by 5.5 times in patients with higher PSA {[}OR = 5.51;p = 0.012 CI 95% (1.435-21.21)]. The recurrence-free survival curve also demonstrates that lower IDO1 was associated with lower time to biochemical recurrence (p = 0.0004). Conclusion The loss of IDO1 expression was associated with increased chance of biochemical recurrence, higher PSA, and a Gleason score in localized PC. (AU)

• FAPESP's process: 10/19525-8 - Analysis and prognostic implication of expression of cell adhesion molecules in localized prostate cancer
• Grantee: Felipe Saraiva Bernardes
• Support Opportunities: Scholarships in Brazil - Scientific Initiation